Jagsonpal Pharmaceuticals has signed a business transfer agreement to acquire the wellness portfolio of Group Pharmaceuticals. The acquisition is valued at an initial consideration of Rs 23.7 crore along with an additional amount based on future sales. This move aims to strengthen Jagsonpal’s pharmaceutical portfolio and enhance its presence in women’s healthcare. Meanwhile, Group Pharma plans to focus its resources on oral care following this divestment.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.